Artiva Biotherapeutics, Inc. ARTV Cumulative Gross Proceeds From Convertible Notes Derivative Instruments And Redeemable Convertible Preferred Stock
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept artv:CumulativeGrossProceedsFromConvertibleNotesDerivativeInstrumentsAndRedeemableConvertiblePreferredStock.
The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Artiva Biotherapeutics, Inc.'s cumulative gross proceeds from convertible notes derivative instruments and redeemable convertible preferred stock.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Artiva Biotherapeutics, Inc.'s cumulative gross proceeds from convertible notes derivative instruments and redeemable convertible preferred stock?
- Artiva Biotherapeutics, Inc. (ARTV) reported cumulative gross proceeds from convertible notes derivative instruments and redeemable convertible preferred stock of $441.8M in Q1 2026.
- How has Artiva Biotherapeutics, Inc.'s cumulative gross proceeds from convertible notes derivative instruments and redeemable convertible preferred stock changed year-over-year?
- Artiva Biotherapeutics, Inc.'s cumulative gross proceeds from convertible notes derivative instruments and redeemable convertible preferred stock increased by 10.0% year-over-year, from $401.7M to $441.8M.